| ²é¿´: 469 | »Ø¸´: 0 | |||
allpeptideÒø³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¿¹¾úëÄLL(17-29)£¬LL-37 FK-13|717919-68-1|FKRIVQRIKDFLR
|
|
ÈËÔ´ÐÔ¿¹¾úëÄLL-37¾ßÓкÜÇ¿µÄ¿¹¾úºÍ¿¹Ñ×»îÐÔ£¬¹ãÆ×¿¹¾úЧ¹ûºÅ£¬µ«ÓÉÓÚÆä·Ö×ÓÁ¿±È½Ï´ó£¬²¢ÇÒÔÚÉúÎïÌåÄÚµÄϸ°ûÑ¡ÔñÐԵͣ¬¼ÓÖ®Éú²ú³É±¾¸ß£¬Òò´ËÏÞÖÆÁËLL-37ÔÚÖÎÁÆ·½ÃæµÄÓ¦Óá£Òò´Ë¿ª·¢³öеÄLL-37ÑÜÉúµÄ¶Ì¦Á-ÂÝÐý¿¹¾úëÄ£¬ÕâÀàÐòÁн϶̵Ŀ¹¾úëľßÓиüºÃµÄϸ°ûÑ¡ÔñÐÔ£¬²¢ÇÒÓëLL-37Ïà±È£¬Æä¿¹Ñ×»îÐÔûÓÐÃ÷ÏÔµÄËðʧ¡£LL-37 FK-13¾ÍÊÇLL-37ÑÜÉúµÄ¶Ì¦Á-ÂÝÐý¿¹¾úëÄÖеÄÒ»ÖÖ£¬ÓÉ13¸ö°±»ùËá×é³É£¬¾ßÓкܸߵÄϸ°ûÑ¡ÔñÐԺͿ¹Ñ×»îÐÔ¡£Ñо¿±íÃ÷LL-37 FK-13¿ÉÒÔͨ¹ýÉøÍ¸Ï¸°ûĤºÍÆÆ»µÄ¤µÄÍêÕûÐÔÀ´É±ËÀ΢ÉúÎïϸ°û¡£ LL-37µÄºËÐÄÐòÁÐFK-13±»¼¡¶¯µ°°×±£»¤ÃâÊÜϸ¾úµ°°×Ë®½â¡£FK-13±íÏÖ³ö¿¹HIV-1¡¢ECµÄ»îÐÔ₅₀ 3.4΢Ãס£ÓÉÓÚN-Ä©¶Ë±½±û°±ËáµÄÈ¥³ýµ¼ÖÂʧ»î£¬FKRIVQRIKDFLR¶ÔÓ¦ÓÚÈËÀàLL-37µÄ×îС¿¹HIVÇøÓò¡£ FK-13, core sequence of LL-37, is protected from bacterial proteolysis by actin. FK-13 showed activity against HIV-1, EC₅₀ 3.4 ¦ÌM. As removal of the N-terminal phenylalanine leads to inactivation, FKRIVQRIKDFLR corresponds to the minimal anti-HIV region of human LL-37. img ±àºÅ: 189236 ÖÐÎÄÃû³Æ: LL(17-29)£¬LL-37 FK-13 Ó¢ÎÄÃû: LL-37 FK-13 trifluoroacetate salt Ó¢ÎÄͬÒå´Ê: Cationic Antimicrobial Protein 18 (150-162) (human), LL-37 (17-29), hCAP18 (150-162) AND LL17 - 29 CASºÅ: 717919-68-1 µ¥×Öĸ: H2N-FKRIVQRIKDFLR-OH Èý×Öĸ: H2N-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-COOH °±»ùËá¸öÊý: 13 ·Ö×Óʽ: C80H135N25O17 ƽ¾ù·Ö×ÓÁ¿: 1719.09 ¾«È··Ö×ÓÁ¿: 1718.05 µÈµçµã(PI): 12.25 pH=7.0ʱµÄ¾»µçºÉÊý: 3.98 ƽ¾ùÇ×Ë®ÐÔ: 0.48461538461538 ÊèË®ÐÔÖµ: -0.44 À´Ô´: È˹¤»¯Ñ§ºÏ³É£¬½öÏÞ¿ÆÑ§Ñо¿Ê¹Ó㬲»µÃÓÃÓÚÈËÌå¡£ ´¿¶È: 95%¡¢98% ÑÎÌåϵ: ¿ÉÑ¡TFA¡¢HAc¡¢HCl»òÆäËü Éú³ÉÖÜÆÚ: 2-3ÖÜ ´¢´æÌõ¼þ: ¸º80¡æÖÁ¸º20¡æ ±êÇ©: ¤ø¿¹¾úëÄ(Antimicrobial Peptides) ¤ø²¡¶¾Ñ§ |
» ²ÂÄãϲ»¶
²ÄÁÏ¿¼Ñе÷¼Á
ÒѾÓÐ7È˻ظ´
270µ÷¼Á
ÒѾÓÐ7È˻ظ´
275ѧ˶081000·þ´Óµ÷¼Áµ½ÆäËûרҵ£¬±£²»×¡±¾×¨ÒµÁË
ÒѾÓÐ6È˻ظ´
0710ÉúÎïѧ£¬325Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
296²ÄÁÏר˶Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
385·Ö ÉúÎïѧ£¨071000£©Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
377Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
¡¾Çóµ÷¼Á¡¿ÐÂÄÜÔ´²ÄÁϱ¾¿Æ£¬Ò»Ö¾Ô¸211£¬³õÊÔ321
ÒѾÓÐ6È˻ظ´
316Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)















»Ø¸´´ËÂ¥